NCT06616155View on ClinicalTrials.gov

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2029

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Interventions
PROCEDURE

Biopsy

Undergo tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Enzalutamide

Given PO

DRUG

Ruxolitinib

Given PO

Trial Locations (3)

48109

RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

NOT_YET_RECRUITING

Karmanos Cancer Institute, Detroit

60612

NOT_YET_RECRUITING

Rush University, Chicago

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER

NCT06616155 - Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter